Lupin receives FDA nod for generic Mepron
Lupin has received the Food and Drug Administration’s clearance for atovaquone oral suspension in a 750 mg/5 mL dosage strength.
The product is a generic version of GlaxoSmithKline’s Mepron oral suspension, 750 mg/5 mL.
Atovaquone oral suspension is indicated for prevention and acute oral treatment of mild-to moderate pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole.
The product has a market value of approximately $117.4 million, according to June 2018 IQVIA data.
The product is a generic version of GlaxoSmithKline’s Mepron oral suspension, 750 mg/5 mL.
Atovaquone oral suspension is indicated for prevention and acute oral treatment of mild-to moderate pneumocystis carinii pneumonia (PCP) in patients intolerant to trimethoprim-sulfamethoxazole.
The product has a market value of approximately $117.4 million, according to June 2018 IQVIA data.